Keywords
How to Cite
Abstract
Patients with stage IV of pancreatic cancer were locally irradiated by 51 Gy total dose (fraction dose was 3 Gy). Gemcytabin, gemsar + carboplatin, or carboplatin + etoposid + 5-fluorouracil were intraarterially administered as chemotherapy preparations. DNA radiosensitivity biomarkers in patient blood were determined before the treatment start. There was revealed interrelation between value of biochemical index and life span patient. The DNA blood radiosensitivity index determinations are enabled to predict personally the results more success treatment in patients with pancreatic cancer after the use of abovementioned regimens of chemoradiotherapy.References
Иванов С.Д. Предиктивные биохимические маркеры ответа на лучевую и химиолучевую терапию онкологических больных // Биомед. химия. - 2012. - Т. 58. - Вып. 6. - С. 635-650.
Иванов С.Д. железо и рак: роль ионов железа в процессе канцерогенеза и при лучевой терапии опухоле-носителей // Усп. соврем. биол. - 2013. - Т. 133. - № 5. - С. 581-594.
Иванов С.Д., Ямшанов В.А., Маслюкова Е.А. Способ определения показаний к проведению органосохраняющего лечения больных раком мочевого пузыря / Пат. на изобр. № 2319963. Бюл. № 8 от 20.03.2008 г.
Каприн А.Д., Старинский В.В., Петрова Г.В. Под ред. Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). - М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России, 2016. - 250 с.
Соухами Р., Тобайас дж. Рак и его лечение: пер. с англ. - М.: БИНОМ. Лаборатория знаний, 2009. - 437 с.
Alix-Panabieres C., Pantel K. Circulating tumor cells: liquid biopsy of cancer // Clin. Chem. - 2013. - Vol. 59. - P 110-118.
Andren-sandberg A. Pancreatic cancer: chemotherapy and radiotherapy // North Am. J. Med. sci. - 2011. - Vol. 3. - № 1. - P. 1-12.
Crowley E., Di Nicolantonio F., Loupakis F., Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood // Nat. Rev. Clin. Oncol. - 2013. - Vol. 10. - P. 472-484.
Ducreux M., Cuhna A.S., Caramella C. et al. Cancer of pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. - 2015. - Vol. 26. - Suppl.5. - Pv56-v68.
Gillmore R., Lawrence V., Raouf s. et al. Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience. // Clin. oncol. - 2010. - Vol. 22. - P. 564-569.
Imamura T., Komatsu s., Ichikawa D. et al. Liquid biopsy in patients with pancreatic cancer: circulating tumor cells and cell-free nucleic acids // World J. Gastroenterol. - 2016. - Vol. 22. - № 25. - P 5627-5641.
Lewis A.R., Valle J.W., McNamara M.G. Pancreatic cancer: Are "liquid biopsies" ready for prime-time? // World J. Gastroenterol. - 2016. - Vol. 32. - № 32. - P. 7175-7185.
Li C.-P., Chao Y., Chi K.-H. et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study // Int. J. Radiat. oncol. Biol. Phys. - 2003. - Vol. 57. - № 1. - P. 98-104.
Li D., Abbruzzese J.L. New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts // Clin. Cancer Res. - 2010. - Vol. 16. - P 4313-4318.
Li G., Huang Y., Manjunath Y. et al. Clinical significance of circulating tumor cells in pancreatic cancer // Biol. Med. (Aligarh). - 2016. - Vol. 8. - № 7. - P. 357-361.
Martini M., Vecchione L., Siena S. et al. Targeted therapies: how personal should we go? // Nature Rev. Clin. Oncol. - 2012. - Vol. 9. - P. 87-97.
Molina-Montes E., Wark P.A., Sanches M.J. et al. Dietary intake of iron, heme-iron and magnesium and pancreatic cancer risk in the European prospective investigation into cancer and nutrition cohort // Int. J. Cancer. - 2012. -Vol. 131. - № 7. - P 47.
Neoptolemos J.P, Stocken D.D., Friess H. et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer // N. Engl. J. Med. -2004. - Vol. 350. - P 1200-1210.
Orditura M., Galizia G., Diana A. et al. Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasisfree survival (DMFS) in early breast cancer: a propensity score-matched analysis // ESMO Open. - 2016. - Vol. 1. - P. e000038.
Park E.S., Jin C., Guo Q. et al. Continuous flow deform-ability-based separation of circulating tumor cells using microfluidic ratchets // Small. - 2016. - Vol. 12. - № 14. - P 1909-1919.
Shibuya K., Oya N., Fujii T. et al. Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer // Am. J. Clin. Oncol. - 2011. - Vol. 34. - № 2. - P. 115-119.
Siegel R., Miller K.D., Jemal A. Cancer statistics // CA Cancer J. Clin. - 2016. - Vol. 66. - P. 7-30.
Tavares-Murta B.M., Mendonca M.A.O., Duarte N.L. et al. Systemic leukocyte alterations are associated with invasive uterine cervical cancer // Int. J. Gynecol. Cancer. - 2010. - Vol. 20. - № 7. - P. 1154-1159.
Tuveson D.A., Neoptolemos J.P. Unrerstanding metastasis in pancreatic cancer: A call for new clinical approaches // Cell. - 2012. - Vol. 20. - P 21-23.
Werner J., Combs S.E., Springfeld C. et al. Advanced-stage pancreatic cancer: therapy options // Nature Rev. Clin. Oncol. - 2013. - Vol. 10. - P. 323-333.
Wolfgang C.I., Herman J.M., Laheru D.A. et al. Recent progress in pancreatic cancer // CA Cancer J. Clin. -2013. - Vol. 63. - P. 318-348.
Yu K.H., Ricigliano M., Hidalgo M. Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response in pancreatic cancer // Clin. Cancer. Res. - 2014. - Vol. 20. - P. 5281-5289.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2017